Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

BRAF NRAS

BRAF NRAS LETTER TO THE EDITOR BRAF and NRAS Muta- study. Molecular analysis revealed mutated melanomas with a low in- 2–5 different BRAF and NRAS mutations cidence. In our experience at the tions are Not Mutually in at least 1 area in 7 of 11 BRAF- cancer molecular genetic platform of mutated or NRAS-mutated tumors. A the Brest University Hospital, using Exclusive in Melanoma tumor also contained 2 BRAFS467L pyrosequencing to search for BRAF and in Single and NRASQ61R mutations within the codon 600 and NRAS codon 61 3 sampled areas. Considering tumor mutations in melanomas following Melanoma Cells heterogeneity and possible BRAF and the guidelines of the French Cancer NRAS, double-mutants is very im- Institute, we only identified a single To the Editor: portant for clinical management of case of double BRAFV600K and patients with metastatic melanomas NRASQ61H mutant among 225 con- We read with interest the study because this mutational status hardly secutive melanoma samples (0.4%) by Chiappetta and colleagues reporting influences the therapeutic strategy. The percentages of allelic mutations BRAF and NRAS mutational status BRAF and NRAS mutations using next-generation sequencing intratumor heterogeneity within nod- were once considered as mutually ex- (NGS) were 52.7% for BRAFV600K ular melanomas. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/braf-nras-saViBh4M3n
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000217
pmid
26317309
Publisher site
See Article on Publisher Site

Abstract

LETTER TO THE EDITOR BRAF and NRAS Muta- study. Molecular analysis revealed mutated melanomas with a low in- 2–5 different BRAF and NRAS mutations cidence. In our experience at the tions are Not Mutually in at least 1 area in 7 of 11 BRAF- cancer molecular genetic platform of mutated or NRAS-mutated tumors. A the Brest University Hospital, using Exclusive in Melanoma tumor also contained 2 BRAFS467L pyrosequencing to search for BRAF and in Single and NRASQ61R mutations within the codon 600 and NRAS codon 61 3 sampled areas. Considering tumor mutations in melanomas following Melanoma Cells heterogeneity and possible BRAF and the guidelines of the French Cancer NRAS, double-mutants is very im- Institute, we only identified a single To the Editor: portant for clinical management of case of double BRAFV600K and patients with metastatic melanomas NRASQ61H mutant among 225 con- We read with interest the study because this mutational status hardly secutive melanoma samples (0.4%) by Chiappetta and colleagues reporting influences the therapeutic strategy. The percentages of allelic mutations BRAF and NRAS mutational status BRAF and NRAS mutations using next-generation sequencing intratumor heterogeneity within nod- were once considered as mutually ex- (NGS) were 52.7% for BRAFV600K ular melanomas.

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Aug 1, 2015

There are no references for this article.